Otsuka Holdings Co.,Ltd. [4578.T]
TOKYO, Mar 27 (Pulse News Wire) – Otsuka Holdings CO.,LTD. (4578.T) announced today that its subsidiary, Otsuka Pharmaceutical Co., Ltd., agreed to acquire Transcend Therapeutics, Inc.
Through its subsidiary Otsuka America Inc. The acquisition, expected to close in the second quarter of fiscal 2026, involves merging a special purpose vehicle established by OAI with Transcend Therapeutics. Current shareholders of Transcend Therapeutics will receive cash consideration for their shares. This move accelerates Otsuka's expansion in mental health treatments, particularly targeting PTSD, which lacks sufficient treatment options despite high prevalence rates in the US.
By integrating TSND-201, a novel drug candidate with a distinct mechanism of action, Otsuka aims to enhance its portfolio and solidify its position as a global leader in developing next-generation therapies. Key details of the transaction include: - Otsuka Pharmaceutical holds 100% of Transcend Therapeutics' shares post-acquisition. - Total consideration includes $100 million upfront and earn-out payments tied to sales milestones. - The deal is subject to customary closing conditions and regulatory approvals.
🟡 Confidence: Standard AI-translated content.